Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
42 |
Employees |
- |
Revenues (TTM) (Millions $) |
0 |
Net Income (TTM) (Millions $) |
-25 |
Cash Flow (TTM) (Millions $) |
24 |
Capital Exp. (TTM) (Millions $) |
0 |
Ocata Therapeutics, Inc.
Ocata Therapeutics, Inc. was a biotechnology company founded in 2004 and based in Marlborough, Massachusetts. The company was initially focused on developing small molecule therapeutic drugs for various diseases, including cancer. However, in 2014, the company shifted its focus to regenerative medicine, particularly in the field of ophthalmology.
Ocata Therapeutics had developed a proprietary technology called induced pluripotent stem cell (iPSC) technology, which allowed them to create specialized cells that have the potential to replace damaged or diseased cells in the human body. Using this technology, the company aimed to develop innovative therapies for degenerative eye conditions, such as age-related macular degeneration (AMD) and Stargardt's disease.
Ocata Therapeutics conducted several clinical trials to evaluate the safety and efficacy of their stem cell-based therapies in treating vision impairment. Their lead product, called OpRegen', was designed to replace the damaged retinal pigment epithelium (RPE) cells in AMD patients. The company also had other programs in their pipeline, including a therapy for Stargardt's disease.
In 2016, Astellas Pharma Inc., a Japanese pharmaceutical company, acquired Ocata Therapeutics and incorporated it into their regenerative medicine subsidiary. The acquisition provided Astellas with a strong foundation in the field of ophthalmology and stem cell therapies.
|